Professor Mella and Dr. Fluge, Haukeland University Hospital, Publication Date: 06/16/2011
Methotrexat (Mtx) is a therapeutic agent with known (but not well understood) immunomodulatory properties.
Given orally on a weekly schedule for rheumatoid arthritis, one of the drug effects is a moderate B-cell depletion, which mechanistically is similar to but not as pronounced as the effect of Rituximab (Edwards et al. NEJM, 2004. Efficacy of B-Cell Targeting Therapy with Rituximab in Patients with Rheumatoid Arthritis).
For one of the three pilot patients (patient 1), she was treated weekly with Methotrexat for the last 22 weeks, also with a significant and moderate clinical response on CFS symptoms, starting from 10 weeks after initiating Mtx.
See also: Professor Mella: Major clinical response after Rituximab treatment in ME/CFS patients